Table 2.

US FDA approved nanomedicines used for cancer treatments

Drug	Class	Platform	Drug carried ratio	Diameter (mm)	Dose (mg2/m)	References
Doxorubicin	Liposome	Doxil®	10,000–15,000	100	25–80	Gabizon et al16 and Hamilton et al138
Vincristine	Liposome	Marqibo	~10,000	100	2.0–2.25	Bedikian et al139 and Silverman and Deitcher140
Daunorubicin	Liposome	Daunoxome	~10,000	50	10–190	Gill et al141 and Bellott et al142
Mertansine	Antibody–drug conjugates	Trastuzumab emtansine	≤8	~10	10–160	Lu et al143
Monomethyl auristan E	Antibody–drug conjugates	Brentuximab vedotin	≤8	~10	90–110	Younes et al144 and Bradley et al145
Paclitaxel	Protein carrier	Abraxane®	>10,000	130	150–300	Ando et al146

Abbreviation: FDA, Food and Drug Administration.